<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00713687</url>
  </required_header>
  <id_info>
    <org_study_id>GEM-658-EBE-0024-I</org_study_id>
    <secondary_id>EudraCT-Nr.: 2008-001560-37</secondary_id>
    <nct_id>NCT00713687</nct_id>
  </id_info>
  <brief_title>Gemcitabine/Oxaliplatin and Photodynamic Therapy in Cholangiocarcinoma</brief_title>
  <acronym>GemOx-PDT</acronym>
  <official_title>Sequential Combination of Chemotherapy With Gemcitabine/Oxaliplatin and Photodynamic Therapy in Advanced Cholangiocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Münchner Studienzentrum</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Technische Universität München</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In patients with cholangiocarcinoma therapeutic effects have been reported for
      Gemcitabine/Oxaliplatin. Furthermore, photodynamic therapy (PDT) has significantly improved
      patients survival in two randomised trials. PDT induces tumor necrosis only in an area of few
      millimetres, while tumor parts which are located beyond this area remain untreated. An
      additive effect could result from PDT as a local therapy in combination with systemic
      chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients entered in the study receive a sequential therapy consisted of photodynamic therapy
      followed by systemic chemotherapy (Gemcitabine/Oxaliplatin) 4 weeks later. Systemic
      chemotherapy every 2 weeks is scheduled 9 times in each cycle. Thereafter, another cycle of
      PDT followed by chemotherapy is intended.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    recruiting failed
  </why_stopped>
  <start_date>August 2008</start_date>
  <completion_date>December 2011</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival 6 months after study start</measure>
    <time_frame>6 months after study start</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival 12 months after study start Progression free interval Overall survival Life quality</measure>
    <time_frame>Until 12 months after study start</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Cholangiocarcinoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment by combination of photodynamic therapy and chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine, Oxaliplatin, Photodynamic therapy (Photosan®)</intervention_name>
    <description>Photodynamic therapy (PDT) after successful drainage:
Photosan® 2 mg/kg i.v. 48 hrs before laser activation
9 cycles of GemOx chemotherapy (start 4 weeks after PDT):
Gemcitabine 1000 mg/m² 100 min infusion on day 1 of chemotherapy
Oxaliplatin 100 mg/m² 2h infusion on day 2 of chemotherapy
iteration every 14 days
afterwards 4 weeks intermission
Iteration of 1. and 2. in case of good compatibility</description>
    <arm_group_label>1</arm_group_label>
    <other_name>No other names</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologic/cytologic verified cholangiocarcinoma or cholangiocarcinoma-typical
             findings in &gt;= 2 diagnostic methods

          -  Bile duct stenoses which are technically successful treated with biliary drainage

          -  Irresectability/inoperability

          -  Karnofsky-Index &gt;= 60%

          -  Age &gt;= 18

          -  Written consent

        Before chemotherapy:

          -  Bilirubin &lt;= 5 mg/dl

          -  GOT/GPT &lt; 5x upper standard

          -  Creatinine &lt; 2x upper standard

          -  Thrombocytes &gt; 100 G/l

          -  Neutrophils &gt; 2,00 G/l

          -  Haemoglobin &gt; 9 g/dl

          -  No occurence of complications during endoscopic procedures (abscess, bilioma,
             cholecystitis, cholangitis, pancreatitis, biliary leakage)

        Exclusion Criteria:

          -  Implantation of a metal stent in the bile duct

          -  Previous PDT or chemotherapy

          -  Neoplasia

          -  Porphyria

          -  Pregnant or breastfeeding women

          -  Women of childbearing age and potent men who are not using highly effective
             contraceptives
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias Ebert, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head of the gastroenterological department of the Klinikum rechts der Isar</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roland M. Schmid, Prof. Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Head of the gastroenterological department of the Klinikum rechts der Isar</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Technical University of Munich at the Klinikum rechts der Isar II. Medizinische Klinik Ismaninger Str. 22</name>
      <address>
        <city>Munich</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Rajagopalan V, Daines WP, Grossbard ML, Kozuch P. Gallbladder and biliary tract carcinoma: A comprehensive update, Part 1. Oncology 2004;18:889-896. Patel T. Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol 2006;3:33-42. de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM. Biliary tract cancers. N Engl J Med. 1999;341:1368-1378. Eckel F, Schmid RM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 2007;96:896-902. Ortner ME, Caca K, Berr F, Liebetruth J, Mansmann U, Huster D, Voderholzer W, Schachschal G, Mössner J, Lochs H. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology 2003;125:1355-1363. Zoepf T, Jakobs R, Arnold JC, Apel D, Riemann JF. Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy. Am J Gastroenterol 2005;100:2426-2430. Wiedmann M, Caca K, Berr F, Schiefke I, Tannapfel A, Wittekind C, Mössner J, Hauss J, Witzigmann H. Neoadjuvant photodynamic therapy as a new approach to treating hilar cholangiocarcinoma: a phase II pilot study. Cancer. 2003;97:2783-2790. Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, Moan J, Peng Q. Photodynamic therapy. J Natl Cancer Inst. 1998;90:889-905. Gollnick SO, Vaughan L, Henderson BW. Generation of effective antitumor vaccines using photodynamic therapy. Cancer Res 2002;62:1604-1608. Wiedmann M, Berr F, Schiefke I, Witzigmann H, Kohlhaw K, Mössner J, Caca K. Photodynamic therapy in patients with non-resectable hilar cholangiocarcinoma: 5-year follow-up of a prospective phase II study. Gastrointest Endosc 2004;60:68-75.</citation>
  </reference>
  <verification_date>July 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2008</study_first_submitted>
  <study_first_submitted_qc>July 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2008</study_first_posted>
  <last_update_submitted>August 9, 2012</last_update_submitted>
  <last_update_submitted_qc>August 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 10, 2012</last_update_posted>
  <keyword>photodynamic therapy</keyword>
  <keyword>PDT</keyword>
  <keyword>gemcitabine</keyword>
  <keyword>oxaliplatin</keyword>
  <keyword>cholangiocarcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

